Aceuity

Aceuity is a clinical-stage biopharmaceutical company dedicated to developing transformative ophthalmic medicines, specifically targeting presbyopia. The company's lead program, ACE-1702, is a novel topical eye drop designed to restore near vision by addressing the loss of lens elasticity or pupil dynamics associated with aging. Aceuity's approach focuses on providing a long-lasting and well-tolerated pharmacological solution as an alternative to corrective lenses or surgery. Headquartered in Menlo Park, California, the company is led by industry veterans with extensive experience in eye care innovation. The company has successfully advanced its lead candidate into Phase 2 clinical trials, demonstrating its commitment to addressing significant unmet needs in vision care. Backed by specialized investors like Chiesi Ventures, Aceuity is positioned to advance the standard of care for millions of individuals affected by age-related vision loss.